Sangamo Therapeutics, Inc
isaralgagene civaparvovec
Fabry disease
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on isaralgagene civaparvovec for Fabry disease is in focus around Date TBD.
Primary source
· SEC 8-K
verified 15h ago
“In December, initiated a rolling submission of a BLA to the FDA seeking approval of isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease, under an Accelerated Approval pathwa”